Ascendis Pharma A/S (ASND)
256.82
+3.37
(+1.33%)
USD |
NASDAQ |
Nov 06, 16:00
256.78
-0.04
(-0.02%)
After-Hours: 20:00
Ascendis Pharma Research and Development Expense (Quarterly) : 85.39M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 85.39M |
| March 31, 2026 | 66.33M |
| December 31, 2025 | 88.09M |
| September 30, 2025 | 76.00M |
| June 30, 2025 | 79.33M |
| March 31, 2025 | 88.88M |
| December 31, 2024 | 82.42M |
| September 30, 2024 | 78.83M |
| June 30, 2024 | 88.35M |
| March 31, 2024 | 74.29M |
| December 31, 2023 | 97.74M |
| September 30, 2023 | 121.23M |
| June 30, 2023 | 114.30M |
| March 31, 2023 | 113.85M |
| December 31, 2022 | 110.80M |
| September 30, 2022 | 98.09M |
| June 30, 2022 | 96.19M |
| March 31, 2022 | 93.33M |
| December 31, 2021 | 75.04M |
| September 30, 2021 | 69.26M |
| June 30, 2021 | 100.44M |
| March 31, 2021 | 106.17M |
| December 31, 2020 | 90.31M |
| September 30, 2020 | 74.87M |
| June 30, 2020 | 70.02M |
| Date | Value |
|---|---|
| March 31, 2020 | 63.36M |
| December 31, 2019 | 53.48M |
| September 30, 2019 | 50.21M |
| June 30, 2019 | 48.23M |
| March 31, 2019 | 57.29M |
| December 31, 2018 | 43.35M |
| September 30, 2018 | 36.65M |
| June 30, 2018 | 47.91M |
| March 31, 2018 | 37.53M |
| December 31, 2017 | 33.01M |
| September 30, 2017 | 34.14M |
| June 30, 2017 | 24.10M |
| March 31, 2017 | 21.96M |
| December 31, 2016 | 21.54M |
| September 30, 2016 | 18.43M |
| June 30, 2016 | 14.99M |
| March 31, 2016 | 17.91M |
| December 31, 2015 | 13.70M |
| September 30, 2015 | 8.934M |
| June 30, 2015 | 13.98M |
| March 31, 2015 | |
| December 31, 2014 | 9.395M |
| September 30, 2014 | 5.209M |
| June 30, 2014 | |
| March 31, 2014 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | 180.52M |
| Novo Nordisk A/S | 2.348B |
| Genmab A/S | 449.53M |
| Zealand Pharma A/S | 80.28M |
| Evaxion AS | 2.331M |